^
    NRG1 overexpression
    Esophageal Squamous Cell Carcinoma
    AV-203
    Sensitive
    :
    C3
    Am J Cancer Res - 3wk
    PD-L1 expression
    Esophageal Squamous Cell Carcinoma
    nivolumab
    Sensitive
    :
    B
    Bristol-Myers Squibb Press Release - 4wk
    PD-L1 expression
    Esophageal Squamous Cell Carcinoma
    nivolumab + ipilimumab
    Sensitive
    :
    B
    Bristol-Myers Squibb Press Release - 4wk
    MRE11A underexpression
    Esophageal Squamous Cell Carcinoma
    cisplatin
    Resistant
    :
    C3
    AACR 2021 - 4wk
    UBQLN4 overexpression
    Esophageal Squamous Cell Carcinoma
    cisplatin
    Resistant
    :
    C3
    AACR 2021 - 4wk
    No biomarker
    Esophageal Squamous Cell Carcinoma
    nivolumab
    Sensitive
    :
    A1
    PD-L1 expression
    Esophageal Squamous Cell Carcinoma
    pembrolizumab
    Sensitive
    :
    A1
    EGFR overexpression
    Esophageal Squamous Cell Carcinoma
    erlotinib
    Sensitive
    :
    B
    No biomarker
    Esophageal Squamous Cell Carcinoma
    tislelizumab
    Sensitive
    :
    B
    NTRK3 fusion
    Esophageal Squamous Cell Carcinoma
    larotrectinib
    Sensitive
    :
    C1
    NTRK2 fusion
    Esophageal Squamous Cell Carcinoma
    larotrectinib
    Sensitive
    :
    C1
    NTRK1 fusion
    Esophageal Squamous Cell Carcinoma
    larotrectinib
    Sensitive
    :
    C1
    EGFR mutation
    Esophageal Squamous Cell Carcinoma
    afatinib
    Sensitive
    :
    C1
    HER-2 positive
    Esophageal Squamous Cell Carcinoma
    trastuzumab
    Sensitive
    :
    C1
    EGFR amplification
    Esophageal Squamous Cell Carcinoma
    afatinib
    Sensitive
    :
    C2
    NDRG1 overexpression
    Esophageal Squamous Cell Carcinoma
    cisplatin + 5-fluorouracil
    Resistant
    :
    C3
    SGK1 overexpression
    Esophageal Squamous Cell Carcinoma
    cisplatin + 5-fluorouracil
    Resistant
    :
    C3
    AFAP1-AS1 overexpression
    Esophageal Squamous Cell Carcinoma
    FP
    Resistant
    :
    C3
    PD-L1 expression
    Esophageal Squamous Cell Carcinoma
    camrelizumab
    Sensitive
    :
    C3
    TLR signature
    Esophageal Squamous Cell Carcinoma
    tislelizumab
    Sensitive
    :
    C3
    NDRG1-H
    Esophageal Squamous Cell Carcinoma
    cisplatin + 5-fluorouracil
    Sensitive
    :
    C3
    DKK1 overexpression
    Esophageal Squamous Cell Carcinoma
    pembrolizumab + DKN-01
    Sensitive
    :
    C3
    DKK1 overexpression
    Esophageal Squamous Cell Carcinoma
    DKN-01
    Sensitive
    :
    C3
    NFKB1 expression
    Esophageal Squamous Cell Carcinoma
    rivoceranib
    Sensitive
    :
    C3
    KDR expression
    Esophageal Squamous Cell Carcinoma
    rivoceranib
    Sensitive
    :
    C3
    PD-L1 overexpression + CCL5 overexpression
    Esophageal Squamous Cell Carcinoma
    Immunotherapy
    Sensitive
    :
    C3
    PD-L1 underexpression
    Esophageal Squamous Cell Carcinoma
    toripalimab + surufatinib
    Sensitive
    :
    C3
    TTN D7145H
    Esophageal Squamous Cell Carcinoma
    cisplatin
    Sensitive
    :
    C3
    MYH4 Q1210fs
    Esophageal Squamous Cell Carcinoma
    cisplatin
    Sensitive
    :
    C3
    VERI is free for non-commercial use, no login needed.
    Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
    For commercial access, including additional premium features, please contact us.
    By using VERI, you are agreeing to our
    and
    Privacy Policy
    ACCEPT COOKIES